NCT00247962

Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 566 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.

Conditions

• Ankylosing Spondylitis

Interventions

Type	Name	Description
DRUG	etanercept	50 mg
DRUG	sulphasalazine (SSZ)	Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.

Timeline

• Start date: 2005-12-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2005-11-02
• Last updated: 2012-11-08
• Results posted: 2012-11-08

Locations

83 sites across 18 countries: Australia, Austria, China, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Qatar, Saudi Arabia, Spain, Sweden, United Kingdom